Molecular Profile | JAK2 V617F |
Therapy | Pictilisib + Ruxolitinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | JAK2 V617F | Advanced Solid Tumor | sensitive | Pictilisib + Ruxolitinib | Preclinical | Actionable | In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790). | 24251790 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(24251790) | Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. | Full reference... |